Skip to content

Category Archives: EVICEL(TM) Liquid Fibrin Sealant

OMRIX Biopharmaceuticals Receives FDA Approval > General Hemostasis in Surgery Indication for EVICEL(TM) Liquid Fibrin Sealant > Adjunct to hemostasis for use in patients undergoing surgery > Partners with Johnson & Johnson’s Ethicon division for biosurgical product line for hemostasis

Friday, January 25, 2008

Does the potential of Fibrin Sealants for minimally invasive surgery remain largely unexplored? Will the FDA approval and general hemostasis in surgery indication for EVICEL expand the market potential? Will EVICEL now actively be promoted for a wider range of surgical applications?

IIP > Read on here…
…the U.S. Food and Drug Administration has granted an expanded […]

Filed in Product candidates for the treatment of immune deficien, Antibody-rich products, Fibrin Patch biological-device convergence product, Developing and marketing protein-based biosurgery, EVICEL(TM) Liquid Fibrin Sealant, Frozen liquid, Requires one minute preparation time after thawing, Clinical data related to three pivotal studies, Passive immunotherapy, Human plasma-derived liquid fibrin sealant, Hybrid and endoluminal treatment options, Hybrid procedures combining endoscopy and laparoscopy, Food and Drug Administration FDA, Clinical and physiologic patterns, Medical Device Company, Johnson & Johnson’s Ethicon division, OMRIX Biopharmaceuticals, Laparoscopy Laparoscopic | Comments (0)